[
    [
        {
            "time": "2018-03-15",
            "original_text": "Novo Nordisk Suing Mylan Over Generic Victoza Drug",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Suing",
                    "Mylan",
                    "Generic",
                    "Victoza",
                    "Drug"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk Suing Mylan Over Generic Victoza Drug",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "Novo Nordisk's Fiasp Gets EC Approval for Label Expansion",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Fiasp",
                    "EC Approval",
                    "Label Expansion"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk's Fiasp Gets EC Approval for Label Expansion",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Denmark's Novo Nordisk files lawsuit against Mylan over patent",
            "features": {
                "keywords": [
                    "Denmark",
                    "Novo Nordisk",
                    "files",
                    "lawsuit",
                    "Mylan",
                    "patent"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Denmark's Novo Nordisk files lawsuit against Mylan over patent",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]